By inhibiting FGFR1 signaling, pemigatinib attenuates tumor cell proliferation, angiogenesis, and resistance mechanisms in FGFR-driven malignancies, including cholangiocarcinoma and urothelial cancers [147]. Here, FGFR1 is linked to neoplasm.